Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XBIO - Xenetic Biosciences, Inc.

Previous close
3.8
0   0%

Share volume: 953
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.45%

PREVIOUS CLOSE
CHG
CHG%
$3.80
0.14
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 0%
Dept financing 5%
Liquidity 49%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.44%
1 Month
1.24%
3 Months
8.20%
6 Months
-1.92%
1 Year
19.94%
2 Year
1,219.35%
Key data
Stock price
$3.80
P/E Ratio 
0.00
DAY RANGE
$3.80 - $3.94
EPS 
$0.00
52 WEEK RANGE
$3.29 - $5.20
52 WEEK CHANGE
$17.19
MARKET CAP 
6.307 M
YIELD 
N/A
SHARES OUTSTANDING 
1.542 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$10,084
AVERAGE 30 VOLUME 
$24,017
Company detail
CEO: Jeffrey F. Eisenberg
Region: US
Website: xeneticbio.com
Employees: 4
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Xenetic Biosciences, Inc. focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology. The company has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC.

Recent news